Time, Fuel, & Money

The Bio-Boom Waiting Game

Reactive founders, unrealistic timelines, and the art of listening before you leap Season 2 | Episode 3 Deborah is live from Advanced Therapies Week in San Diego, Vassili is on his way, and Karim is holding down the conversation from wherever the year of the Horse has him pointed. The Lunar New Year transition sets the tone: bold, forward, and honest about what the last season taught them. The episode opens on a pattern Deborah keeps running into at conferences — founders and dealmakers who lead with money before they've earned the right to the conversation. The irony she puts plainly: you can be in the same room as some of the most valuable minds in biotech, and people will skip past them chasing a hundred-dollar bill taped under a chair. Karim brings in The Obstacle Is the Way — not as motivational content, but as a genuine frame for how to stop reacting and start reading situations clearly. Events are neutral. We assign them meaning. Rockefeller understood this when everyone else was panicking during the Depression. Most early-stage founders don't, which is why "18 months to clinical trial" keeps showing up in decks that have no business saying it. The conversation gets specific: the language barrier between academic medicine and venture capital, why leading with patient impact actually pushes investors away, and what it really takes to get into the manufacturing queue before you even have your IND enabling studies mapped. Deborah's analogy — the Baby Boom daycare waitlist problem applied to biotech — is one of the cleaner frames this show has produced. The close is quieter: boldness this year might not mean charging forward. It might mean listening to yourself clearly enough to know when to pivot, and trusting that the uncoiling actually leads somewhere.

Break the Pressure Loop

Doomscrolling, dopamine myths, and choosing real connection over noise Season 2 | Episode 2 Season 2 continues with a familiar voice back in the conversation. Deborah Karim and Vassili open the year reflecting on what has been quietly draining people’s energy and attention and why it feels harder than ever to slow down. Deborah, Karim, and Vassili unpack why doomscrolling isn’t really about “the internet,” but about an internal need for relief—especially when pressure (from society or from ourselves) starts to feel constant. They challenge the common “dopamine = pleasure” narrative, reframing dopamine as part of the reward system—not the thing that actually creates happiness—and explore how modern commerce and social platforms exploit that loop. The conversation also draws a line between empty consumption and real restoration. Karim shares how baking (and even making espresso) becomes a meditative process—an example of using effort to reconnect with yourself rather than numb out. Deborah adds the nuance: social media can be useful when it drives action and learning, but it becomes “brain rot” when it replaces living. They close on relationships: the difference between community and transaction. If you’re building only to “get something,” the relationship is already on borrowed time. The alternative is simpler—and harder: show up without an agenda, reduce the pressure you’re carrying, and choose connection that gives energy back. This episode is about noticing the loop, naming it, and breaking it—so you can feel better and build better.

Season 2 Begins Mastering What You Can Control

Fuel focus and building relationships when the noise is loud Season 2 | Episode 1 Season 2 opens with a reset. In this kickoff episode, Deborah and Karim reflect on JPM week and the quiet discipline it takes to move through crowded rooms without getting pulled into noise. Instead of chasing every event or optimizing for visibility, they focus on what’s actually controllable: energy, attention habits, and how they show up for people. The conversation explores why rushing creates transactional energy and why meaningful relationships are built by slowing down and staying present. They discuss protecting fuel through sleep food movement and boundaries, and how small intentional choices compound over time into trust, leverage, and clarity. The episode also looks inward at goal setting and self-assessment. Not every target needs to be hit to make progress, and growth often means recalibrating priorities rather than adding more. By replacing unhelpful habits with better ones and focusing on stewardship over short-term wins, founders and operators create durability in uncertain markets. Season 2 will bring more guests, more behind-the-scenes building, and more signal for the community. This episode sets the posture for the year ahead calm focused and grounded in what actually moves things forward.

BLPN: Delivery Wins. Help First. Build Anyway.

Fundraising, platform leverage, and the relationships that make biotech move. BLPN Series | Episode 4 of 4 As JPM week approaches, we close the BLPN Series with a founder conversation that sits right at the intersection of science, capital, and the human reality of building. Deborah and Karim are joined by Regina Leung, CEO of Sylamore Bio, a gene therapy company advancing rare disease programs while building a CNS delivery platform designed to cross the blood-brain barrier. Regina shares how Silimot is using a dual-track strategy: moving a lead rare-disease indication toward the clinic while leveraging platform partnerships to validate the tech, generate revenue, and de-risk development. The conversation gets practical about what “raising in a hard market” actually looks like: why platform companies are often misunderstood, why chasing buzzwords backfires, and why founders are better served by 10 high-quality conversations than “a thousand frogs.” We also unpack the operational side—how to scale a team carefully, avoid hiring mistakes, and stay disciplined when partnership milestones demand more capacity. We end where biotech always ends: with patients. Regina shares a sobering reminder of what’s at stake in ultra-rare disease—and why optimism isn’t naïve when it’s paired with execution, humility, and community. This episode is about staying authentic, building the right relationships, and remembering that delivery—of drugs, of leadership, of help—wins.

BLPN | Build Something That Actually Works

Technology, trust, and doing the work when no one is watching BLPN Series | Episode 3 of 4 As JPM Healthcare Conference week approaches, this episode of the BLPN Series shifts the focus from headlines and hype to what it really takes to move science forward: durable technology, patient outcomes, and teams willing to do the hard, unglamorous work. In this conversation, Deborah and Karim are joined by Alex Herzlinger of Highland Instruments to explore what it means to build neurotechnology that actually delivers impact. Alex walks through Highland’s non-invasive brain stimulation platform, the long road of NIH-backed clinical validation, and why Parkinson’s disease became their go-to-market focus. The discussion moves beyond pitch decks into clinical reality—what patients experience, how functional improvement restores independence, and why rigor matters more than novelty. Drawing on Alex’s background in the military, medtech commercialization, and entrepreneurship, the episode highlights a recurring BLPN theme: progress comes from consistency, humility, and collaboration—not shortcuts. We talk about earning trust with data, aligning technology with real clinical workflows, and how communities like BLPN help founders sharpen execution rather than posture for attention. This episode is about substance over shine, building for patients first, and showing up prepared when it’s finally time to step onto the JPM stage.